Sentient Jet at the Forefront of Sustainability in Private Aviation Industry With Over 300% Emissions Offset Projected For 2022
Sentient Jet, a Directional Aviation company and category innovator, is set to surpass its notable 2021 sustainability efforts of offsetting one of, if not the highest amount of emissions of any private aviation company with the first half of 2022 on the rise. As a multi-million-dollar annual investment at no cost to its card owners, Sentient Jet’s strong commitment to sustainability continues to set a new industry standard while offering a more thoughtful way to fly.
Sentient Jet launched its emissions-neutral sustainability initiative at the start of 2021 and promptly achieved the largest emissions offset of any private aviation company, with a 300% offset across 30,000 legs flown through the year.
Sentient’s offsets represent the equivalent of planting 345,000 acres and nearly 5,000,000 trees in the U.S. or providing the energy for an entire average U.S. town for a full year, according to current U.S. Census Bureau estimates for 2021. Sentient Jet’s carbon offset program supports a variety of renewable energy and forest conservation projects around the world and continues to fund projects to mitigate not only CO2 but non-CO2 impact and improve communities globally.
“We chose to focus on a more comprehensive offsetting program, as we knew this was the best method to help reduce the footprint of our client’s flights while also taking definitive steps to reducing emission levels. Within 18 months we’re extremely pleased with the success of this program, but of course we’re always looking for ways to improve and evolve our ongoing sustainability efforts,” said Andrew Collins, President and CEO of Sentient Jet. “We hope Sentient Jet’s sustainability efforts can become an example for what the private aviation industry as a whole can accomplish in terms of making meaningful steps toward reducing overall emissions and prioritizing our planet.”
At the heart of Sentient Jet’s unique sustainability initiative is the company’s investment and partnership with environmental leader 4AIR, the first and only rating system focused on comprehensive sustainability in private aviation. Sentient Jet’s carbon offset program goes beyond traditional aviation sustainability programs by offsetting all aviation emissions, including water vapor, aerosols, and nitrous oxide, which together account for two-thirds of the emissions an aircraft produces when flying.
“Sentient Jet continues to demonstrate true leadership by committing all of its flights to 4AIR’s Emissions Neutral level on behalf of its clients. Sentient goes beyond just carbon neutrality, addressing the impact from CO2 and non-CO2 emissions in a truly comprehensive fashion,” says Kennedy Ricci, President, 4AIR.
Jet Card owners can book by calling (866) 602-0044 or visiting www.sentient.com.
About Sentient Jet
Founded in 1999 with the invention of the Jet Card, and now an integral part of Directional Aviation, Sentient Jet is one of the most innovative private aviation companies across the globe. The Sentient Jet Card offers clients the flexibility and convenience of flying private for their personal and business air travel needs along with a host of unique digital booking tools, including an industry-first with instant, automated text-based booking, a unique sustainability program, and an outstanding service heritage. Sentient Jet is known for its commitment to safety and is guided by an Independent Safety Advisory Board with former FAA and NTSB officials. Sentient Jet’s extensive network of certified operators ensures that clients will always have access to executive aircraft that meet their rigorous standards for safety and quality. Visit sentient.com for more information. You can also follow Sentient Jet on social media platforms, including Twitter , Facebook and Instagram. Download the Sentient Jet Mobile App: iOS | Android .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005080/en/
Contact information
Daphna Barzilay
Maverick Creative
daphna@maverickcreative.us
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom